NA-Selank

NA-Selank (N-Acetyl Selank Amidate) is a chemically modified analog of Selank, itself a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the V.V. Zakusov Institute of Pharmacology, by extending the naturally occurring immunomodulatory tetrapeptide tuftsin with a C-terminal Pro-Gly-Pro extension to improve metabolic stability.

NA-Selank carries two further chemical modifications relative to parent Selank: N-terminal acetylation (protecting against degradation by aminopeptidase enzymes) and C-terminal amidation (protecting against degradation by carboxypeptidase enzymes). Its full sequence is Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, molecular formula C35H59N11O10, molecular weight approximately 793.93 g/mol, CAS number 864070-44-0 (we note some sources report a slightly different formula and molecular weight, likely reflecting differences in salt form or reporting conventions across vendors — researchers should confirm exact specifications with their specific supplier).

At Verified Peptides, we think it is important to state directly what we found — and did not find — in researching this specific compound: despite a genuine, decades-long Russian academic research literature on parent Selank (described in detail below), we could not locate any independently published, peer-reviewed study specifically evaluating NA-Selank itself. This modified analog appears to originate from the commercial research-peptide supply industry, engineered using well-established peptide-stabilization chemistry (N-acetylation and C-amidation are standard, well-understood modifications used across many peptides), rather than from the same academic institute research program responsible for Selank's own substantial evidence base.

This distinction between an original, academically-developed peptide and a commercially-engineered "improved" derivative is worth understanding as a broader pattern in the research-peptide industry, not something unique to NA-Selank: it is common for supply companies to introduce chemically modified versions of well-known peptides — adding acetylation, amidation, PEGylation, or other stabilizing modifications — based on generally sound peptide-chemistry principles, without commissioning or awaiting the same kind of dedicated pharmacological characterization and publication that the original compound underwent through academic research channels.

At Verified Peptides, we think it's essential for researchers to understand the specific evidentiary structure of NA-Selank clearly: it is a stabilized chemical derivative of a well-studied parent compound, but the derivative itself lacks its own dedicated, independently published research base. Parent Selank, by contrast, has a genuine multi-decade research history from Russian academic institutions, including the GABAergic gene-expression study described above (PMID 26924987), pharmacological comparison work with tuftsin (PMID 19803361), and intranasal administration research (PMID 18841804), among other studies published primarily in Russian pharmacology journals and, increasingly, in international venues like Frontiers in Pharmacology.

We want to be clear about the logical gap this creates for NA-Selank specifically: research demonstrating Selank's GABAergic and anxiolytic-relevant effects does not automatically establish that N-Acetyl Selank Amidate produces identical effects at an equivalent potency, despite the chemical similarity. Peptide modifications that improve metabolic stability can, in principle, also alter receptor binding kinetics, tissue distribution, or other pharmacological properties in ways that are not necessarily predictable from the parent compound's data alone — this is a general principle in peptide pharmacology, not a specific criticism of NA-Selank, but it is a meaningful reason researchers should not treat NA-Selank's presumed effects as equivalent to established Selank findings without independent verification.

No FDA, EMA, or other Western regulatory body has evaluated or approved either Selank or NA-Selank for any indication (Selank has reported use as an approved nasal-drop anxiolytic product in Russia specifically, distinct from Western regulatory pathways). At Verified Peptides, we sell research-grade NA-Selank exclusively for laboratory research, and we encourage researchers interested in this specific modified analog to design experiments that directly test its properties rather than assuming equivalence with published Selank data.

The two chemical modifications defining NA-Selank — N-terminal acetylation and C-terminal amidation — are among the most common and well-understood peptide-stabilization strategies used broadly across peptide chemistry, not techniques unique or proprietary to this specific compound. Acetylation caps the free N-terminal amine (a common site for aminopeptidase attack), while C-terminal amidation replaces the free carboxylic acid group with an amide (protecting against carboxypeptidase attack) — both modifications are used across numerous approved and investigational peptide drugs to extend functional half-life.

Selank's parent compound, tuftsin (the natural immunomodulatory tetrapeptide Selank was engineered from by adding a Pro-Gly-Pro extension), is itself a genuine, independently characterized endogenous peptide with its own research history in immunology, distinct from the anxiolytic/nootropic research profile that Selank itself has been developed for — illustrating how a single natural peptide fragment can serve as the starting point for engineered derivatives studied in entirely different research contexts.

Selank is reportedly used as an approved nasal-drop anxiolytic pharmaceutical product within Russia specifically, a regulatory status that does not extend to NA-Selank, Western markets, or FDA/EMA jurisdictions — researchers should not conflate Selank's specific Russian regulatory status with any status for the modified NA-Selank analog discussed in this profile.

The absence of dedicated, independently published research specifically on NA-Selank is a pattern researchers should recognize as common across the broader commercial research-peptide industry: chemically modified "improved" versions of well-studied parent peptides are frequently developed and marketed by supply companies based on generally sound peptide-chemistry principles, without the modified version itself necessarily undergoing the same rigorous, independently published characterization as the original academic-institute-developed compound.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade NA-Selank we offer, with a Certificate of Analysis (COA) available for each lot. As a modified 7-residue peptide with defined N-terminal acetylation and C-terminal amidation, correct confirmation of both terminal modifications, not just overall amino acid composition, is important for verifying authentic NA-Selank identity.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Given the reporting inconsistencies we noted in molecular formula and weight across different vendor sources, researchers should request specific analytical confirmation (mass spectrometry) directly from their supplier rather than relying solely on generic product descriptions.

Lyophilized NA-Selank is stable when stored at -20°C, protected from light and moisture, and researchers can generally expect the unreconstituted peptide to maintain integrity over an extended period under these conditions. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with bacteriostatic water or another appropriate sterile diluent, NA-Selank solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation. The N-terminal acetylation and C-terminal amidation modifications are specifically intended to improve resistance to enzymatic degradation relative to unmodified Selank, which may confer somewhat improved stability in biological matrices, though this has not been independently confirmed through dedicated stability studies specific to this analog.

Researchers should avoid repeated freeze-thaw cycles of reconstituted material and should follow the specific storage guidance provided with each lot's documentation to preserve sample validity for research use.